1. 首页
  2. 产品目录

LDE225 (NVP-LDE225,Erismodegib),Smoothened(Smo)拮抗剂

LDE225 (NVP-LDE225,Erismodegib) （订货以英文为准）

编号：L127562
CAS号：956697-53-3
分子式：C26H26F3N3O3
分子量：485.50
货号 品牌 包装 目录价 您的价格 库存 数量 购买
L127562-10mg 阿拉丁 10mg ¥407.90
请登录
L127562-50mg 阿拉丁 50mg ¥1465.90
请登录
L127562-100mg 阿拉丁 100mg ¥2100.90
请登录
产品名称 LDE225 (NVP-LDE225,Erismodegib)
中文名称 LDE225 (NVP-LDE225,Erismodegib),Smoothened(Smo)拮抗剂
CAS号 956697-53-3
分子式（M.F.） C26H26F3N3O3
分子量（M.W.） 485.50
储存条件 -20°C储存
溶解性DMSO >60 mg/mL Ethanol >60 mg/mL
存贮条件储存温度-20°C
产品介绍LDE225 (NVP-LDE225,Erismodegib)是一种Smoothened(Smo)拮抗剂，抑制Hedgehog (Hh)信号通路，IC50分别为1.3 nM (小鼠)和2.5 nM(人)。
备注LDE225 (NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. Phase 3.
生化机理LDE225 is an orally bioavailable small-molecule Smoothened (Smo) antagonist with potential antineoplastic activity. LDE225 selectively binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.
别名NVP-LDE225; rel-N-[6-[(2R,6S)-2,6-二甲基-4-吗啉基]-3-吡啶基]-2-甲基-4'-(三氟甲氧基)-[1,1'-联苯]-3-甲酰胺;LDE 225;NVP-LDE 225;Erismodegib;LDE-225; rel-N-[6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide
搜索质检报告(COA)
搜索MSDS
相关产品